Kadah Basel Al, Niewald Marcus, Papaspyrou George, Dzierma Yvonne, Schneider Mathias, Schick Bernhard
Department of Otorhinolaryngology, Saarland University Medical Center, Kirrberger Straße, 66421, Homburg/Saar, Germany.
Department of Radiotherapy and Radiooncology, Saarland University Medical Center, Homburg/Saar, Germany.
Eur Arch Otorhinolaryngol. 2016 Jun;273(6):1543-7. doi: 10.1007/s00405-015-3636-3. Epub 2015 Apr 24.
Brachytherapy has become an established therapeutic regimen for primary, persistent, recurrent and metastatic tumour disease in the head and neck region. This study presents the authors' preliminary experience with intracavitary brachytherapy by means of an individual silicone applicator in the treatment of patients with nasal, sinonasal, orbital and nasopharyngeal cancer. Between January 2001 and January 2013, twenty patients with cancer of the nasal cavity, the paranasal sinuses and nasopharynx underwent surgery and intracavitary brachytherapy with the aid of an individually manufactured silicone applicator in the Department of Otolaryngology, Head and Neck Surgery and in the Department of Radiotherapy and Radiooncology at the Saarland University Medical Center of Homburg, Germany. The tumour was localized in the nasal cavity/paranasal sinuses (15) affecting the orbit twice and the nasopharynx (5). There were 14 patients with squamous cell carcinoma, 2 patients with mixed tumours and one patient with adenocarcinoma, adenoid cystic carcinoma, mucosal melanoma or plasmocytoma. The majority of the patients presented with advanced disease (T3 or T4 tumours). In 18/20 patients, brachytherapy was performed as a boost technique, in the remaining two solely because of a previous radiation series. All surgical interventions were performed endonasally. Three to six weeks after surgery, a cast of the nasal cavity was created under general anaesthesia. Subsequently, an individual brachytherapy silicon applicator with two to four plastic tubes was manufactured. The radiation therapy was applied using the Ir-192 high-dose-rate-afterloading method (total dose 10-20 Gy) in two to five sessions, additionally in 18/20 patients a percutaneous radiotherapy with a total dose of 30-60 Gy was applied. After a mean duration of follow-up of 2 years, 7/20 patients experienced a local progression, 5/19 a regional recurrence in the neck nodes and 4/19 distant metastases. The 2-year survival was 57.3 %. No serious complications were reported. The silicone applicator was well tolerated by all patients. Because of the complexity of the sinonasal anatomy with the finding of mainly advanced tumours, the presented individual silicone brachytherapy applicator has proven to be useful and meaningful for endocavitary brachytherapy of malignancies of the nasal cavities, paranasal sinuses and nasopharynx.
近距离放射治疗已成为头颈部原发性、持续性、复发性和转移性肿瘤疾病的既定治疗方案。本研究介绍了作者使用个体化硅胶施源器进行腔内近距离放射治疗鼻腔、鼻窦、眼眶和鼻咽癌患者的初步经验。2001年1月至2013年1月期间,20例鼻腔、鼻窦和鼻咽癌患者在德国洪堡萨尔州大学医学中心耳鼻咽喉头颈外科和放射治疗与放射肿瘤学系,借助个体化制造的硅胶施源器接受了手术和腔内近距离放射治疗。肿瘤位于鼻腔/鼻窦(15例),累及眼眶2次,鼻咽部(5例)。有14例鳞状细胞癌患者,2例混合瘤患者,1例腺癌、腺样囊性癌、黏膜黑色素瘤或浆细胞瘤患者。大多数患者表现为晚期疾病(T3或T4肿瘤)。18/20例患者中,近距离放射治疗作为一种强化技术进行,其余2例仅因先前的放疗疗程而进行。所有手术均经鼻进行。术后3至6周,在全身麻醉下制作鼻腔模型。随后,制造一个带有两到四根塑料管的个体化近距离放射治疗硅胶施源器。采用Ir-192高剂量率后装方法进行放射治疗(总剂量10-20Gy),分两到五个疗程进行,另外18/20例患者还进行了总剂量为30-60Gy的经皮放射治疗。平均随访2年后,20例患者中有7例出现局部进展,19例中有5例颈部淋巴结区域复发,19例中有4例远处转移。2年生存率为57.3%。未报告严重并发症。所有患者对硅胶施源器耐受性良好。由于鼻窦解剖结构复杂,且主要发现为晚期肿瘤,所介绍的个体化硅胶近距离放射治疗施源器已被证明对鼻腔、鼻窦和鼻咽部恶性肿瘤的腔内近距离放射治疗有用且有意义。